TRICHOME Pharma, a Spanish pharmaceutical company specialized in medicinal-grade cannabis and hemp-derived consumer healthcare, announces that it has received approval from the Spanish Agency of Medicines and Medical Devices (AEMPS) to cultivate medicinal cannabis for research purposes.
The company is also thrilled to announce the launch of its new website, inviting visitors to explore and learn more about the business.
Trichome Pharma was founded in 2020 with the ambitious goal of helping to shape a future where cannabis is considered a viable alternative in mainstream healthcare for patients and consumers.
Over the past 18 months, the company has been operating in stealth mode while building its research and development platform, with the aim of broadening access to medicinal cannabis and setting a new benchmark in quality and innovation for medicinal-grade starter materials and finished products.
With their research license secured, Trichome Pharma can advance a full pipeline of projects to the next phase, including the development of novel micropropagation and conservation techniques for large-scale plant production, the study and selection of various cannabis cultivars from their bank of genetics, and the development of innovative cultivation strategies and protocols to optimize plant quality, performance
“Receiving AEMPS approval is a significant milestone for the company that marks the culmination of many months of hard work.
“It’s a really exciting time to be in this industry. I’ve always believed that Spain is the perfect place to build and grow a cannabis business. Not only does it possess a world class agricultural sector and optimal climatic conditions for cannabis cultivation, but it also has a rich ecosystem of knowledgeable industry experts and a deeply-rooted culture in cannabis.
“Of course, we’d love to see domestic regulation evolve in the same way other European markets
have and trust this will happen in the not too distant future.” Says Nicholas Balk, CEO of Trichome Pharma and Managing Director of Trichome Capital.
The market for regulated cannabis in Europe continues to grow in leaps and bounds, while positive momentum is building on the supply side in Spain, with the list of entities (both public and private) holding cultivation licenses from AEMPS growing to 21.
Trichome Pharma believes it will set itself apart through its focus on sustainable cultivation and innovation coming from its R&D platform. The company has a lot more of exciting projects and news to share, which it looks forward to announcing in the weeks to come.